SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

BNTX

BioNTech SE
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat and $1B buyback provide near-term support, but the 35% revenue decline and widening losses underscore the COVID-19 revenue cliff. Watch for pumitamig Phase 2 data at ASCO (May 29-June 2) and gotistobart interim Phase 3 data in 2026, positive readouts could re-rate the stock on oncology optionality. The manufacturing restructuring signals management is serious about cost discipline, but execution risk is high.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$95.50
T+0 close · May 5, 2026 · via day close
Latest settled
−2.77%
T+60 · $92.85
Vs SPY
−5.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $95.50entry
  2. T+1 · 7mo ago −0.25%α −1.64% · $95.26
  3. T+5 · 6mo ago −2.26%α −4.25% · $93.34
  4. T+20 · 6mo ago −6.66%α −11.61% · $89.14
  5. T+60 · 4mo ago −2.77%α −5.51% · $92.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which beat the consensus EPS estimate of -$1.92 by ~35%. The company reaffirmed full-year 2026 revenue guidance of €2.0B-€2.3B and announced a planned $1B share repurchase program and a major manufacturing footprint consolidation expected to yield ~€500M in annual savings by 2029. However, the core COVID-19 vaccine business continues to decline, and the oncology pipeline, while advancing with multiple pivotal trial initiations, remains pre-commercial.

Key Financial Metrics

EPS
−$2.46
est −$1.92 · +28.1%
Revenue
$127.0M
est $155.4M · -18.3% · -35.4% YoY
Rating
in line
Guidance
€2,000M-€2,300M
maintained
Gross Margin
39.5%

Key Facts

  • Q1 2026 revenue €118.1M vs €182.8M YoY (-35%), driven by lower COVID-19 vaccine sales
  • GAAP diluted EPS -€2.10 (-$2.46) vs consensus -$1.92, a 34.9% beat
  • Net loss widened to -€531.9M from -€415.8M YoY; adjusted net loss -€494.6M
  • Reaffirmed FY2026 revenue guidance €2.0B-€2.3B and adjusted R&D spend €2.2B-€2.5B
  • Planned $1.0B ADS repurchase program over 12 months for capital efficiency
  • Manufacturing footprint consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites, affecting ~1,860 positions; ~€500M annual savings targeted by 2029
  • Five pivotal trials for pumitamig (PD-L1/VEGF-A bispecific) initiated in Q1 2026 in collaboration with BMS
  • Cash, cash equivalents, and security investments of €16.8B as of March 31, 2026
  • Co-founders Sahin and Türeci to transition to new mRNA company by end of 2026; CEO search initiated

Financial Impact

Revenue decline of €64.7M YoY (-35%); net loss increased by €116.1M; $1B buyback authorized; ~€500M annual cost savings targeted by 2029

revenuenet lossR&D expensescash position

Risk Factors

  • COVID-19 vaccine revenue continues to decline faster than oncology pipeline can offset
  • Manufacturing consolidation may incur significant upfront exit costs and operational disruption
  • Co-founder transition creates leadership uncertainty; new CEO appointment is a key overhang
  • Oncology pipeline remains pre-revenue; late-stage trial failures would reset valuation
  • $1B buyback may be viewed as capital allocation signal but does not fix declining fundamentals

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287464

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026